299 related articles for article (PubMed ID: 24025942)
1. Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus.
Taylor TN; Alter SP; Wang M; Goldstein DS; Miller GW
Neuropharmacology; 2014 Jan; 76 Pt A(0 0):97-105. PubMed ID: 24025942
[TBL] [Abstract][Full Text] [Related]
2. Reduced vesicular monoamine transport disrupts serotonin signaling but does not cause serotonergic degeneration.
Alter SP; Stout KA; Lohr KM; Taylor TN; Shepherd KR; Wang M; Guillot TS; Miller GW
Exp Neurol; 2016 Jan; 275 Pt 1(Pt 1):17-24. PubMed ID: 26428905
[TBL] [Abstract][Full Text] [Related]
3. A vesicular sequestration to oxidative deamination shift in myocardial sympathetic nerves in Parkinson's disease.
Goldstein DS; Sullivan P; Holmes C; Miller GW; Sharabi Y; Kopin IJ
J Neurochem; 2014 Oct; 131(2):219-28. PubMed ID: 24848581
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological inactivation of the vesicular monoamine transporter can enhance 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of midbrain dopaminergic neurons, but not locus coeruleus noradrenergic neurons.
German DC; Liang CL; Manaye KF; Lane K; Sonsalla PK
Neuroscience; 2000; 101(4):1063-9. PubMed ID: 11113355
[TBL] [Abstract][Full Text] [Related]
5. Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration.
Caudle WM; Richardson JR; Wang MZ; Taylor TN; Guillot TS; McCormack AL; Colebrooke RE; Di Monte DA; Emson PC; Miller GW
J Neurosci; 2007 Jul; 27(30):8138-48. PubMed ID: 17652604
[TBL] [Abstract][Full Text] [Related]
6. Restoration of Noradrenergic Function in Parkinson's Disease Model Mice.
Cui K; Yang F; Tufan T; Raza MU; Zhan Y; Fan Y; Zeng F; Brown RW; Price JB; Jones TC; Miller GW; Zhu MY
ASN Neuro; 2021; 13():17590914211009730. PubMed ID: 33940943
[TBL] [Abstract][Full Text] [Related]
7. Dopaminergic D2 receptor is a key player in the substantia nigra pars compacta neuronal activation mediated by REM sleep deprivation.
Proença MB; Dombrowski PA; Da Cunha C; Fischer L; Ferraz AC; Lima MM
Neuropharmacology; 2014 Jan; 76 Pt A():118-26. PubMed ID: 24012539
[TBL] [Abstract][Full Text] [Related]
8. Age-related decline in striatal dopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson's disease.
Colebrooke RE; Humby T; Lynch PJ; McGowan DP; Xia J; Emson PC
Eur J Neurosci; 2006 Nov; 24(9):2622-30. PubMed ID: 17100850
[TBL] [Abstract][Full Text] [Related]
9. Decreased vesicular storage and aldehyde dehydrogenase activity in multiple system atrophy.
Goldstein DS; Sullivan P; Holmes C; Kopin IJ; Sharabi Y; Mash DC
Parkinsonism Relat Disord; 2015 Jun; 21(6):567-72. PubMed ID: 25829070
[TBL] [Abstract][Full Text] [Related]
10. Is Parkinson's disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum.
Pifl C; Rajput A; Reither H; Blesa J; Cavada C; Obeso JA; Rajput AH; Hornykiewicz O
J Neurosci; 2014 Jun; 34(24):8210-8. PubMed ID: 24920625
[TBL] [Abstract][Full Text] [Related]
11. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
[TBL] [Abstract][Full Text] [Related]
12. Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity.
Taylor TN; Caudle WM; Shepherd KR; Noorian A; Jackson CR; Iuvone PM; Weinshenker D; Greene JG; Miller GW
J Neurosci; 2009 Jun; 29(25):8103-13. PubMed ID: 19553450
[TBL] [Abstract][Full Text] [Related]
13. Transgenic Mice Expressing Human α-Synuclein in Noradrenergic Neurons Develop Locus Ceruleus Pathology and Nonmotor Features of Parkinson's Disease.
Butkovich LM; Houser MC; Chalermpalanupap T; Porter-Stransky KA; Iannitelli AF; Boles JS; Lloyd GM; Coomes AS; Eidson LN; De Sousa Rodrigues ME; Oliver DL; Kelly SD; Chang J; Bengoa-Vergniory N; Wade-Martins R; Giasson BI; Joers V; Weinshenker D; Tansey MG
J Neurosci; 2020 Sep; 40(39):7559-7576. PubMed ID: 32868457
[TBL] [Abstract][Full Text] [Related]
14. Short-term atrazine exposure causes behavioral deficits and disrupts monoaminergic systems in male C57BL/6 mice.
Lin Z; Dodd CA; Filipov NM
Neurotoxicol Teratol; 2013; 39():26-35. PubMed ID: 23770127
[TBL] [Abstract][Full Text] [Related]
15. Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosis.
Guillot TS; Shepherd KR; Richardson JR; Wang MZ; Li Y; Emson PC; Miller GW
J Neurochem; 2008 Sep; 106(5):2205-17. PubMed ID: 18643795
[TBL] [Abstract][Full Text] [Related]
16. Effect of the weaver mutation on the expression of dopamine membrane transporter, tyrosine hydroxylase and vesicular monoamine transporter in dopaminergic neurons of the substantia nigra and the ventral tegmental area.
Adelbrecht C; Agid Y; Raisman-Vozari R
Brain Res Mol Brain Res; 1996 Dec; 43(1-2):291-300. PubMed ID: 9037545
[TBL] [Abstract][Full Text] [Related]
17. Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats.
Srinivasan J; Schmidt WJ
Eur J Neurosci; 2003 Jun; 17(12):2586-92. PubMed ID: 12823465
[TBL] [Abstract][Full Text] [Related]
18. MPTP Mouse Model of Preclinical and Clinical Parkinson's Disease as an Instrument for Translational Medicine.
Mingazov ER; Khakimova GR; Kozina EA; Medvedev AE; Buneeva OA; Bazyan AS; Ugrumov MV
Mol Neurobiol; 2018 Apr; 55(4):2991-3006. PubMed ID: 28456940
[TBL] [Abstract][Full Text] [Related]
19. Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease.
Goldstein DS; Sullivan P; Holmes C; Miller GW; Alter S; Strong R; Mash DC; Kopin IJ; Sharabi Y
J Neurochem; 2013 Sep; 126(5):591-603. PubMed ID: 23786406
[TBL] [Abstract][Full Text] [Related]
20. Inverse relationship between the contents of neuromelanin pigment and the vesicular monoamine transporter-2: human midbrain dopamine neurons.
Liang CL; Nelson O; Yazdani U; Pasbakhsh P; German DC
J Comp Neurol; 2004 May; 473(1):97-106. PubMed ID: 15067721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
